Cibus (CBUS) Capital Leases (2017 - 2024)

Cibus (CBUS) posted Capital Leases of $119000.0 for Q2 2024, up 2.59% sequentially from $116000.0 in Q1 2024.

Cibus (CBUS) Capital Leases (2017 - 2024) Analysis & Trends

Cibus has reported Capital Leases for 8 years, with the latest figure at $119000.0 in Q2 2024.

Quarterly Capital Leases changed N/A year-over-year to $119000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $119000.0 (changed N/A YoY) and the FY2023 annual result came in at $113000.0, changed N/A from the prior year.
Capital Leases rose to $119000.0 in Q2 2024 per CBUS's latest filing, from $116000.0 in the prior quarter.
Over five years, Capital Leases peaked at $18.2 million in Q1 2020 and troughed at $37000.0 in Q2 2022.
A 5-year average of $10.2 million and a median of $17.5 million in 2021 frame the typical range for Capital Leases.
The sharpest annual moves came in 2020 and 2022: Capital Leases climbed 0.18% in 2020, then slumped 99.79% in 2022.
Over 5 years, Capital Leases stood at $17.9 million in 2020, then retreated by 2.07% to $17.5 million in 2021, then slumped by 99.79% to $37000.0 in 2022, then soared by 205.41% to $113000.0 in 2023, then rose by 5.31% to $119000.0 in 2024.
According to Business Quant data, Capital Leases over the past three periods registered $119000.0, $116000.0, and $113000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cibus	129.72 Mn	109.29 Mn	-

Download Data